HLA-C and melanoma: Further, Aarntzen and colleagues demonstrated improved clinical outcome of melanoma patients receiving a vaccine consisting of DCs pulsed with MHC class I and II restricted epitopes compared to DCs pulsed with MHC class I restricted epitopes only [103].